Kevin Mcculloch Buys 25,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Kevin Mcculloch purchased 25,000 shares of the company's stock in a transaction dated Friday, June 13th. The stock was purchased at an average price of $4.38 per share, for a total transaction of $109,500.00. Following the completion of the purchase, the insider now owns 1,708,585 shares in the company, valued at approximately $7,483,602.30. The trade was a 1.48% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Xeris Biopharma Price Performance

Shares of XERS stock traded up $0.04 during trading hours on Thursday, hitting $4.58. The stock had a trading volume of 1,879,997 shares, compared to its average volume of 1,997,771. The stock has a market capitalization of $716.22 million, a price-to-earnings ratio of -15.27 and a beta of 0.71. Xeris Biopharma Holdings, Inc. has a one year low of $2.03 and a one year high of $6.07. The stock's 50-day moving average price is $4.56 and its two-hundred day moving average price is $4.14.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The firm had revenue of $57.80 million during the quarter, compared to the consensus estimate of $57.61 million. As a group, equities research analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

XERS has been the subject of a number of recent research reports. Leerink Partners boosted their price objective on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research report on Friday, March 7th. Piper Sandler reissued a "neutral" rating and set a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Oppenheimer increased their target price on Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Finally, Wall Street Zen cut Xeris Biopharma from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Xeris Biopharma presently has an average rating of "Moderate Buy" and an average price target of $6.25.

Institutional Investors Weigh In On Xeris Biopharma

A number of hedge funds have recently bought and sold shares of XERS. NewEdge Advisors LLC bought a new stake in shares of Xeris Biopharma in the 4th quarter worth about $34,000. Apella Capital LLC bought a new stake in Xeris Biopharma during the first quarter worth approximately $55,000. Xponance Inc. bought a new stake in Xeris Biopharma during the first quarter worth approximately $57,000. FORA Capital LLC purchased a new stake in Xeris Biopharma during the first quarter valued at approximately $60,000. Finally, FNY Investment Advisers LLC bought a new stake in shares of Xeris Biopharma in the 1st quarter valued at approximately $63,000. Hedge funds and other institutional investors own 42.75% of the company's stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.